Flinn IW - Search Results

1

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Byrd JC, et al. Among authors: flinn iw. N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19. N Engl J Med. 2013. PMID: 23782158 Free PMC article. Clinical Trial.

2

Introduction: chronic lymphocytic leukemia.

Byrd JC, Flinn IW, Grever MR. Byrd JC, et al. Among authors: flinn iw. Semin Oncol. 1998 Feb;25(1):4-5. Semin Oncol. 1998. PMID: 9482520 No abstract available.

3

Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.

Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E, Grever MR. Byrd JC, et al. Among authors: flinn iw. Blood. 1998 Nov 15;92(10):3804-16. Blood. 1998. PMID: 9808574 Free article.

4

Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.

Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR. Byrd JC, et al. Among authors: flinn iw. Blood. 1999 Aug 15;94(4):1401-8. Blood. 1999. PMID: 10438728 Free article.

5

Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.

Byrd JC, Grever MR, Waselenko JK, Willis CR, Park K, Goodrich A, Lucas MA, Shinn C, Flinn IW. Byrd JC, et al. Among authors: flinn iw. Semin Oncol. 2000 Apr;27(2 Suppl 5):37-40. Semin Oncol. 2000. PMID: 10877050

6

Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.

Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T, Piantadosi S, Seifter E, Ambinder RF, Vogelsang G, Grever MR. Flinn IW, et al. Blood. 2000 Jul 1;96(1):71-5. Blood. 2000. PMID: 10891432 Free article. Clinical Trial.

7

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW. Byrd JC, et al. Among authors: flinn iw. J Clin Oncol. 2001 Apr 15;19(8):2153-64. doi: 10.1200/JCO.2001.19.8.2153. J Clin Oncol. 2001. PMID: 11304767 Clinical Trial.

8

Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia.

Waselenko JK, Grever MR, Shinn CA, Flinn IW, Byrd JC. Waselenko JK, et al. Among authors: flinn iw. Leuk Res. 2001 Jun;25(6):435-40. doi: 10.1016/s0145-2126(00)00106-5. Leuk Res. 2001. PMID: 11337014

9

UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.

Byrd JC, Shinn C, Willis CR, Flinn IW, Lehman T, Sausville E, Lucas D, Grever MR. Byrd JC, et al. Among authors: flinn iw. Exp Hematol. 2001 Jun;29(6):703-8. doi: 10.1016/s0301-472x(01)00649-x. Exp Hematol. 2001. PMID: 11378265 Free article.

10

Carboxyamido-triazole (CAI)--a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells.

Waselenko JK, Shinn CA, Willis CR, Flinn IW, Grever MR, Byrd JC. Waselenko JK, et al. Among authors: flinn iw. Leuk Lymphoma. 2001 Sep-Oct;42(5):1049-53. doi: 10.3109/10428190109097725. Leuk Lymphoma. 2001. PMID: 11697622

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

205 results

Search Page